Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Adelene_Perkins
|
| gptkbp:collaboratedWith |
gptkb:AbbVie
gptkb:Roche |
| gptkbp:focus |
drug discovery
cancer therapeutics |
| gptkbp:foundedYear |
1995
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Infinity Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
eganelisib
|
| gptkbp:researchArea |
immuno-oncology
PI3K pathway inhibitors |
| gptkbp:status |
gptkb:public_company
|
| gptkbp:stockSymbol |
gptkb:INFI
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.infi.com/
|
| gptkbp:bfsParent |
gptkb:Stuart_Schreiber
|
| gptkbp:bfsLayer |
4
|